The demand for Lipid-Lowering Agents in Chile has been on the rise in recent years.
Customer preferences: Chile has a high prevalence of cardiovascular diseases, and the population is becoming increasingly aware of the benefits of managing their cholesterol levels. As a result, there has been a growing demand for lipid-lowering agents in the country. Patients are also seeking more effective and convenient treatment options, which has led to an increase in the use of combination therapies.
Trends in the market: The market for lipid-lowering agents in Chile is expected to continue growing in the coming years. The introduction of new drugs and combination therapies is driving this growth. Additionally, there is a growing trend towards personalized medicine, and patients are increasingly demanding treatments that are tailored to their individual needs. This has led to the development of new drugs that target specific types of cholesterol.
Local special circumstances: One of the unique factors influencing the market for lipid-lowering agents in Chile is the country's healthcare system. The public healthcare system in Chile is highly centralized, and the government regulates drug prices. This has led to lower drug prices compared to other countries in the region, making treatment more affordable for patients. However, this also means that drug manufacturers have to navigate a complex regulatory environment to enter the market.
Underlying macroeconomic factors: Chile has one of the strongest economies in South America, with a growing middle class and a high level of urbanization. This has led to an increase in healthcare spending and a growing demand for high-quality healthcare services. Additionally, the country has a rapidly aging population, which is driving demand for healthcare services. These underlying macroeconomic factors are expected to continue driving growth in the market for lipid-lowering agents in Chile.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
